MeduGate LMS;

22nd Oct, 2026 12:00 AM

Test

FDA Approves First Generic Hormone Therapy Patch

The FDA has approved the first generic version of Climara Pro (Bayer), a once-weekly hormone therapy patch, to treat moderate-to-severe menopausal symptoms and prevent osteoporosis in postmenopausal women, according to a press release from the agency.

The patch delivers 0.045 mg estradiol and 0.015 mg of levonorgestrel daily. The combination helps reduce the risk of endometrial hyperplasia, or abnormal thickening of the uterine lining, which can occur when estrogen is used alone, according to the FDA.

The approval comes as the demand for menopause hormone therapy has increased, making some estrogen patches harder to find. The FDA said in September that it was working with manufacturers of estradiol patches to increase supplies and help ensure patches remain available to patients.

The approval is also part of a larger effort from the FDA to make generic medication more affordable and available to patients and increase access to healthcare, according to the release.

Article Key Points

First generic Climara Pro approved for menopausal symptoms + osteoporosis prevention.
Once-weekly patch delivers estradiol 0.045 mg + levonorgestrel 0.015 mg/day.
Progestin component ↓ estrogen-associated endometrial hyperplasia risk in intact uterus.
Indicated for postmenopausal women with intact uterus; avoid in breast cancer history.
Avoid with VTE/arterial thrombosis, liver disease, undiagnosed bleeding, hypersensitivity.

Dive Deeper

How does transdermal estrogen compare with oral therapy for VTE risk?

Which menopausal patients benefit most from combined hormone patches?

What monitoring is recommended during transdermal menopausal hormone therapy?

The patch is approved for postmenopausal women who have an intact uterus experiencing menopausal symptoms. Patients who have been diagnosed with breast cancer or have a history of breast cancer should not use the medication, according to the release.

SUGGESTED FOR YOU

The FDA also advises against use in patients with estrogen-dependent neoplasia, active or prior blood clots (such as deep vein thrombosis or pulmonary embolism), active or prior arterial thromboembolic disease, undiagnosed abnormal genital bleeding, liver disease, or known hypersensitivity to the ingredients.

The most common side effects include site reactions at the site of application, vaginal bleeding, breast and back pain, upper respiratory infection, depression, headache, and flu syndrome, according to the release.

Dive Deeper

Commonly Asked by HCPs

Q: What are guideline-based options for menopausal vasomotor symptom management?

A: Menopausal vasomotor symptoms are commonly treated with systemic hormone therapy when symptom burden is moderate to severe and nonhormonal measures are insufficient. Transdermal and oral estrogen options are used, with route and dose chosen based on symptom control needs, cardiovascular risk profile, adverse-effect concerns, and patient preference.

Read full answer

Q: When is combined estrogen-progestin therapy preferred over estrogen alone?

A: Combined estrogen-progestin therapy is generally used in postmenopausal women with an intact uterus to reduce the risk of endometrial hyperplasia and endometrial cancer from unopposed estrogen. Estrogen alone is typically reserved for women without a uterus, while regimen selection also considers bleeding risk, tolerability, and duration of therapy.

Read full answer

Q: Which patients should avoid systemic menopausal hormone therapy because of contraindications?

A: Systemic menopausal hormone therapy is generally avoided in patients with estrogen-dependent malignancy, active or prior venous thromboembolism, prior arterial thromboembolic disease, unexplained vaginal bleeding, active liver disease, or significant hypersensitivity concerns. Breast cancer history is a major contraindication or strong caution area, and risk stratification is central before prescribing.

Read full answer

Q: What role does menopausal hormone therapy play in osteoporosis prevention?

A: Menopausal hormone therapy can help prevent bone loss and reduce fracture risk in selected postmenopausal women, particularly when vasomotor symptom treatment is also needed. It is not usually first-line solely for osteoporosis prevention, so clinicians often compare its role with calcium, vitamin D, weight-bearing exercise, and osteoporosis-specific pharmacotherapy based on overall fracture risk.

Read full answer

Q: How should clinicians monitor adverse effects during transdermal menopausal hormone therapy?

A: Monitoring during transdermal hormone therapy focuses on symptom response, blood pressure, breast symptoms, abnormal uterine bleeding, local skin reactions, and new thromboembolic or neurologic symptoms. Clinicians also reassess ongoing indication, lowest effective dose, duration of use, and whether new contraindications have emerged over time.

Read full answer